Since the FAK/Src cascade promotes the G1‐S transition (Pickup et al, 2014), we wanted to exclude that the observed tumor growth defects in the combo treatment were arising from FAK or Src direct inhibition. This evidence concerns the gene PTK2 and neoplasm.